Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance
1998

Impact of Alpha-Fetoprotein Surge in Testicular Cancer Treatment

Sample size: 669 publication Evidence: high

Author Information

Author(s): R de Wit, L Collette, R Sylvester, PHM de Mulder, DT Sleijfer, WW ten Bokkel Huinink, SB Kaye, AT van Oosterom, E Boven, G Stoter

Primary Institution: Rotterdam Cancer Institute and University Hospital

Hypothesis

Does a surge in serum alpha-fetoprotein after chemotherapy initiation indicate worse prognosis in non-seminomatous testicular cancer?

Conclusion

An alpha-fetoprotein surge after chemotherapy initiation is a strong adverse prognostic factor for disease progression.

Supporting Evidence

  • Of 352 patients with elevated AFP, 101 (29%) had a surge.
  • An AFP surge was retained in the final model for progression.
  • HCG surge showed no prognostic significance for progression or survival.

Takeaway

If a patient with testicular cancer has a spike in a certain blood marker after starting treatment, it might mean their cancer is not responding well.

Methodology

The study analyzed serum alpha-fetoprotein and human chorionic gonadotrophin levels in patients treated with cisplatin combination chemotherapy, assessing the prognostic significance of marker surges.

Limitations

The study's findings on survival were not statistically significant due to low event numbers.

Participant Demographics

Patients treated between 1983 and 1991 for non-seminomatous testicular cancer.

Statistical Information

P-Value

0.005

Confidence Interval

1.28-4.04

Statistical Significance

p=0.005

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication